Real-World Data About Treatment Pattern and Outcomes of Patients With Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in France: Results From the Fregat Database

G Piessen (1) , A Adenis (2) , F Renaud (1) , S Devaux (1) , D Bergeat (3) , F El Hajbi (4) , N Regenet , Jean-Marc Régimbeau (5, 6) , J Gricar , P Singh (7) , C Paul (8) , M Baklouti (9) , C Thomas (10) , C Emery , E Torreton , F Fagnani

1 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
2 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
3 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
4 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
5 CHU Amiens-Picardie
6 SSPC - Simplification des soins chez les patients complexes - UR UPJV 7518
7 IRFU - Institut de Recherches sur les lois Fondamentales de l'Univers
8 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
9 Bristol-Myers Squibb Company
10 CHU Nantes - Centre Hospitalier Universitaire de Nantes

Esophageal cancer is the seventh most common cancer and sixth leading cause of cancer death, worldwide, with approximately 600,000 new cases and over 540,000 deaths in 2020. Squamous-cell carcinoma accounts for approximately 60% of cases in Europe. The study aim was to describe real-world treatment and outcomes of French patients presenting with UnResectable Advanced, or Metastatic Esophageal Squamous-Cell Carcinoma (URAM-ESCC) from 2014 to 2019 before approval of immune-checkpoint inhibitors (ICI).

Domaines: Médecine humaine et pathologie

G Piessen, A Adenis, F Renaud, S Devaux, D Bergeat, et al.. Real-World Data About Treatment Pattern and Outcomes of Patients With Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma in France: Results From the Fregat Database. Value in Health, 2022, 25 (12), pp.S473 ; RWD123. ⟨10.1016/j.jval.2022.09.2348⟩. ⟨hal-04031810⟩